ESMO

Lower Keytruda Doses May Be as Effective as Standard Doses for Stage 4 NSCLC

September 30th 2024, 1:00pm

Article

Patients with stage 4 non-small cell lung cancer may derive an equal benefit with a lower dose of Keytruda versus the standard dose.

Side Effects, Quality of Life Important to Consider in Breast Cancer Subset

September 29th 2024, 3:00pm

Article

Patients with HER2-positive metastatic breast cancer may consider related side effects and quality of life outcomes when choosing treatments.

Cediranib Added to Lynparza Didn’t Improve Progression, Survival in Ovarian Cancer

September 26th 2024, 9:00pm

Article

A Lynparza/cediranib combo had similar results versus standalone Lynparza among patients with relapsed platinum-sensitive ovarian cancer.

Imjudo Plus Imfinzi Improve Survival Versus Nexavar in Liver Cancer

September 26th 2024, 1:00pm

Article

In patients with unresectable liver cancer, treatment with Imjudo plus Imfinzi showed better survival outcomes compared with Nexavar.

Survival Benefit Continues at 10 Years From Opdivo Either Alone or With Yervoy in Advanced Melanoma

September 25th 2024, 1:00pm

Article

Findings from the CheckMate 067 of patients with advanced melanoma include the longest follow-up of a checkpoint inhibitor in any tumor type.

Krazati Associated With Superior Outcomes Than Docetaxel in KRAS G12C+ NSCLC

September 24th 2024, 9:00pm

Article

Krazati’s benefits were seen regardless of baseline brain metastases, researchers have reported in findings from the KRYSTAL-12 trial.

Imfinzi Improves Survival Outcomes in Subgroups of Patients with LS-SCLC

September 24th 2024, 1:00pm

Article

Among patients with limited-stage small cell lung cancer, the benefits of consolidation Imfinzi were seen across a number of subgroups.

Nubeqa Plus ADT Outperformed ADT Alone in Treating Prostate Cancer

September 23rd 2024, 9:00pm

Article

Adding Nubeqa to androgen deprivation therapy improved radiographic progression-free survival in patients with metastatic hormone-sensitive prostate cancer.

Enhertu Maintains QOL, Slows Pain in HR+/HER2 Metastatic Breast Cancer

September 23rd 2024, 1:00pm

Article

Enhertu improved the time it took for patients with a breast cancer subset to experience worsening pain and other symptoms, without affecting overall quality of life.

Challenges to Consider While Receiving Fotivda for Kidney Cancer

September 21st 2024, 2:00pm

Video

At the 2024 ESMO Congress, CURE® spoke with an expert about Fotivda and certain challenges patients may experience, such as side effects.